Sugi Predict

Sugi Predict / Compounds / Acridine

Acridine

Acridine

SCHEMBL618774

NC(N)=S.c1ccc2nc3ccccc3cc2c1

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.71
▸ MAPT P10636 4/20 0.71
▸ HPGD P15428 3/20 0.71
▸ GLA P06280 2/20 0.71
▸ ACHE P22303 1/20 0.71
▸ HTR3A P46098 1/20 0.57
▸ KDM4E B2RXH2 4/20 0.50
▸ GAA P10253 4/20 0.50
▸ POLB P06746 3/20 0.50
▸ NPC1 O15118 2/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ LMNA P02545 2/20 0.50
▸ IKBKB O14920 1/20 0.50
▸ PTBP1 P26599 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ RCE1 Q9Y256 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ NQO2 P16083 1/20 0.48
▸ TLR8 Q9NR97 4/20 0.47
▸ STAT3 P40763 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acridine SCHEMBL17141399 0.87 ALDH1A1 (0.83) ALDH1A1MAPTHPGDGLAACHE
Acridine SCHEMBL18921100 0.86 ALDH1A1 (0.71) ALDH1A1MAPTHPGDGLAACHE
Acridine SCHEMBL4972293 0.84 ALDH1A1 (1.00) ALDH1A1MAPTHPGDGLAACHE
Acridine SCHEMBL1772714 0.84 ALDH1A1 (1.00) ALDH1A1MAPTHPGDGLAACHE
Acridine SCHEMBL29352289 0.84 ALDH1A1 (1.00) ALDH1A1MAPTHPGDGLAACHE
Acridine SCHEMBL8339 0.84 ALDH1A1 (1.00) ALDH1A1MAPTHPGDGLAACHE
Acridine SCHEMBL3045498 0.84 ALDH1A1 (1.00) ALDH1A1MAPTHPGDGLAACHE
Acridine SCHEMBL4854060 0.84 ALDH1A1 (0.68) ALDH1A1MAPTHPGDGLAACHE
Acridine SCHEMBL28646458 0.82 ALDH1A1 (0.83) ALDH1A1MAPTHPGDGLAACHE
Acridine SCHEMBL641951 0.82 ALDH1A1 (0.94) ALDH1A1MAPTHPGDGLAACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108250182-B 1, 8-naphthamide (2-R group acridine group) thiourea silver ion probe and preparation method thereof 广西中医药大学 2020-10-23 — — CN claimed
CN-108299299-B 4-propylamino-1, 8-naphthalimide-7-benzo [ c ] acridine thiourea and preparation method and application thereof 广西中医药大学 2021-04-20 — — CN disclosed
CN-108299299-B 4-propylamino-1, 8-naphthalimide-7-benzo [ c ] acridine thiourea and preparation method and application thereof 广西中医药大学 2021-04-20 — — CN disclosed
CN-108250182-B 1, 8-naphthamide (2-R group acridine group) thiourea silver ion probe and preparation method thereof 广西中医药大学 2020-10-23 — — CN disclosed
CN-105412108-B 2- methoxyl group -9- acridines（To methoxy benzamide base）Application of the thiocarbamide in acetylcholinesterase inhibitor is prepared 广西中医药大学 2018-07-10 — — CN disclosed
CN-105476992-B Application of the 2- methoxyl group -9- acridine benzamido thiocarbamides in acetylcholinesterase inhibitor is prepared 广西中医药大学 2018-07-06 — — CN disclosed
CN-105476992-A Application of 2-methoxy-9-acridine benzamido thiourea in preparation of acetylcholinesterase inhibitor UNIV GUANGXI CHINESE MEDICINE 2016-04-13 — — CN disclosed
CN-105412108-A Application of 2-methoxy-9-acridine(4-methoxybenzamido) thiourea to preparing of acetylcholin esterase inhibitor UNIV GUANGXI CHINESE MEDICINE 2016-03-23 — — CN disclosed
US-9090640-B2 Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof WAKE FOREST UNIVERSITY 2015-07-28 — — US disclosed
US-8906896-B2 Platinum acridine anti-cancer compounds and methods thereof WAKE FOREST UNIVERSITY 2014-12-09 — — US disclosed
US-20140193334-A1 Targeted Delivery and Prodrug Designs for Platinum-Acridine Anti-Cancer Compounds and Methods Thereof WAKE FOREST UNIVERSITY 2014-07-10 — — US disclosed
WO-2013033430-A1 TARGETED DELIVERY AND PRODRUG DESIGNS FOR PLATINUM-ACRIDINE ANTI-CANCER COMPOUNDS AND METHODS THEREOF WAKE FOREST SCHOOL OF MEDICINE (US) 2013-03-07 — — WO disclosed
US-20120039800-A1 Platinum Acridine Anti-Cancer Compounds And Methods Thereof WAKE FOREST UNIVERSITY 2012-02-16 — — US disclosed
EP-2358203-A1 PLATINUM ACRIDINE ANTI-CANCER COMPOUNDS AND METHODS THEREOF Wake Forest University (US) 2011-08-24 — — EP disclosed
WO-2010048499-A1 PLATINUM ACRIDINE ANTI-CANCER COMPOUNDS AND METHODS THEREOF WAKE FOREST UNIVERSITY (US) 2010-04-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120039800-A1 Platinum Acridine Anti-Cancer Compounds And Methods Thereof ACR, TP53, BAD ALDH1A1 360/4885MAPT 4443/4885HPGD 1753/4885
US-20140193334-A1 Targeted Delivery and Prodrug Designs for Platinum-Acridine Anti-Cancer Compounds and Methods Thereof ERBB3, EGFR, ESR1 ALDH1A1 2873/4885MAPT 4409/4885HPGD 3589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.